- Structure-based drug design of novel and highly potent pyruvate dehydrogenase kinase inhibitors
-
Pyruvate dehydrogenase kinases (PDHKs) are fascinating drug targets for numerous diseases, including diabetes and cancers. In this report, we describe the result of our structure-based drug design from tricyclic lead compounds that led to the discovery of highly potent PDHK2 and PDHK4 dual inhibitors in enzymatic assay. The C3-position of the tricyclic core was explored, and the PDHK2 X-ray structure with a representative compound revealed a novel ATP lid conformation in which the phenyl ring of Phe326 mediated the interaction of the Arg258 sidechain and the compound. Compounds with amide linkers were designed to release the ATP lid by forming an intramolecular pi-pi interaction, and these compounds showed single-digit nM IC50 values in an enzymatic assay. We also explored the C4-position of the tricyclic core to reproduce the interaction observed with the C3-position substitution, and the pyrrolidine compound showed the same level of IC50 values. By optimizing an interaction with the Asn255 sidechain through a docking simulation, compounds with 2-carboxy pyrrole moiety also showed single-digit nM IC50 values without having a cation-pi interaction with the Arg258 sidechain.
- Bessho, Yuki,Akaki, Tatsuo,Hara, Yoshinori,Yamakawa, Maki,Obika, Shingo,Mori, Genki,Ubukata, Minoru,Yasue, Katsutaka,Nakane, Yoshitomi,Terasako, Yasuo,Orita, Takuya,Doi, Satoki,Iwanaga, Tomoko,Fujishima, Ayumi,Adachi, Tsuyoshi,Ueno, Hiroshi,Motomura, Takahisa
-
-
- Total synthesis and absolute stereochemistry of the proteasome inhibitors cystargolides A and B
-
The absolute stereochemistry of the cystargolides was determined by total synthesis. Evaluation of synthetic cystargolides and derivatives showed that the natural (2S,3R) stereochemistry is essential for activity. Moreover, benzyl esters (-)-10 and (-)-15
- Tello-Aburto, Rodolfo,Hallada, Liam P.,Niroula, Doleshwar,Rogelj, Snezna
-
supporting information
p. 10127 - 10130
(2015/10/28)
-
- SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME
-
The present invention provides compounds of Formula (I), pharmaceutical compositions comprising a compound of Formula (I), and methods of treatment of stroke; inflammatory diseases such as rheumatoid arthritis or inflammatory bowel disease; septic shock; reperfusion injury; Alzheimer's disease; shigellosis; and multiple sclerosis.
- -
-
Page/Page column 18; 26
(2010/02/12)
-
- A general method for the synthesis of enantiomerically pure β- substituted, β-amino acids through α-substituted succinic acid derivatives
-
A general procedure for the synthesis of enantiopure β-substituted, β- amino acids is presented. Alkylation of the sodium enolates derived from chiral N-acyloxazolidinone imides 2 (R = Me, i-Pr, t-Bu, Ph, Bn) with tert- butyl bromoacetate afforded the 2-substituted succinate derivatives 3 in good yields (82-89%) and with high selectivity (≥ 93;7). Following hydrolysis, Curtius rearrangement of the resulting carboxylic acid provided the enantiopure benzyloxycarbonyl (Cbz)-protected β-amino esters 6 in good yields (74-79%).
- Evans, David A.,Wu, Leester D.,Wiener, John J. M.,Johnson, Jeffrey S.,Ripin, David H. B.,Tedrow, Jason S.
-
p. 6411 - 6417
(2007/10/03)
-